Respiratory Distress Syndrome
Conditions
Brief summary
When babies are born premature, they often need help with their breathing. The equipment used to help them breathe is not very comfortable and they sometimes need to be put on a specialized breathing machine with a tube into their lungs. The breathing machine or ventilator can be damaging to the newborn's lungs and more damage can occur the longer the newborn stays on a ventilator leading to chronic lung disease later in their lives. A new device called neurally adjusted ventilatory assist or NAVA is available that the investigators believe may be more comfortable for the premature newborn and may help the baby come off breathing support sooner. When using this device, babies may not need to be put on a ventilator and can avoid the lung damage associated with the breathing tube and the ventilator. The objective of this pilot study is to compare this new breathing device called NAVA, to the equipment that is currently being used, called SiPAP, to support premature newborn's breathing after birth without a breathing tube. The investigators hope to show that with this new technology, premature newborns that are having a difficult time breathing, will come off breathing support sooner compared to the breathing machines that are currently being used. The hypothesis for this proposed study is that improved synchrony with noninvasive NAVA will decrease time spent on noninvasive ventilation and avoid intubation.
Interventions
Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
DEVICESiPAP - placebo
The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
Sponsors
Fraser Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
28 Weeks to 32 Weeks
Healthy volunteers
No
Inclusion criteria
* Infants born greater than or equal to 28+0 weeks and less than or equal to 31+6 weeks gestation * Diagnosis of RDS in the first 24 hours of life requiring respiratory support * Parental consent obtained
Exclusion criteria
* Infants with a major congenital anomaly * Infants with pulmonary hypoplasia * Infants known or suspected to have a neuromuscular disorder * Infants less than 28+0 weeks GA * Intubated infants that are likely to require continued mechanical ventilation * Infants requiring vigorous resuscitation at birth, including chest compressions +/- cardiac medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total duration of respiratory support which includes both days and hours on NAVA/SiPAP (DORS) | one year |
Secondary
| Measure | Time frame |
|---|---|
| All cause mortality during the hospitalization | one year |
| Bronchopulmonary dysplasia defined as oxygen requirements or ventilatory support needs at 36 weeks CGA | one year |
| Number of doses of surfactant | one year |
| Incidence of pneumothorax | one year |
| Proportion of infants that required escalation to increased noninvasive respiratory support (BiPhasic or increasing NAVA levels) or intubation and mechanical ventilation | one year |
| Incidence of nasal deformities, specifically nasal erosions | one year |
| Time to reach full volume feeds (at least 120 ml/kg/day) | one year |
| Time to regain birth weight | one year |
| Total length of hospital stay | one year |
| Total duration of oxygen requirement | one year |
Countries
Canada
Outcome results
None listed